4d Molecular Therapeutics, INC

4D Molecular Therapeutics announced positive 2-year data from its Phase 2b PRISM trial for 4D-150, showing consistent visual acuity, disease control, and significant treatment burden reduction in wet AMD patients.

4D Molecular Therapeutics has entered into a significant loan and security agreement with Hercules Capital, Inc., potentially providing up to $200 million in term loans to fund its operations and development.

4D Molecular Therapeutics appointed CFO Kristian Humer as Principal Accounting Officer, succeeding Ashoo Gupta, effective March 25, 2026.

4D Molecular Therapeutics announced full year 2025 financial results, highlighted by rapid Phase 3 trial enrollment for 4D-150 and a strengthened financial position.

4D Molecular Therapeutics exchanged common stock for pre-funded warrants with key institutional investors, adjusting its capital structure.

4D Molecular Therapeutics announced a leadership transition, a new board appointment, and an estimated $514 million in cash, cash equivalents, and marketable securities.

4D Molecular Therapeutics reports increased Q3 2025 net losses amid strategic pipeline prioritization, significant capital raises, and positive clinical trial progress for 4D-150 and 4D-710.

4D Molecular Therapeutics reports accelerated Phase 3 timelines for its lead wet AMD gene therapy, 4D-150, alongside positive DME data and a strategic workforce reduction to extend cash runway.

4D Molecular Therapeutics focuses on advancing 4D-150 and 4D-710, seeking strategic alternatives for other clinical programs, and reports a net loss of $48.0 million for Q1 2025.

4D Molecular Therapeutics reports a net loss of $43.8 million for the third quarter of 2024, with increased research and development expenses and a decrease in collaboration revenue compared to the same period in 2023.

4D Molecular Therapeutics reports a net loss of $34.95 million for the second quarter of 2024, alongside updates on clinical trials and financial activities.

4D Molecular Therapeutics reports a net loss of $32.4 million for the first quarter of 2024, while significantly increasing cash reserves through a public offering.

4D Molecular Therapeutics reports significant progress in its gene therapy pipeline, including positive clinical data for 4D-150 and 4D-710, and a major collaboration with Otsuka Pharmaceutical, while navigating substantial net losses and a strategic workforce reduction.

4D Molecular Therapeutics' 10-K filing details the company's financial results for 2024 and provides updates on its key clinical programs, including 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis.

4D Molecular Therapeutics details a new executive appointment, compensation agreements, and provides updates on its clinical and preclinical programs in recent SEC filings.

David Kirn, See Remarks and a Director of 4D Molecular Therapeutics, Inc., sold 58,333 shares of common stock on July 9, 2026.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, reports transactions involving the purchase and sale of company stock.

Shawn Tomasello, a Director at 4D Molecular Therapeutics, Inc., acquired 50,000 stock options under the company's non-employee director compensation program.

Charles Theuer, a Director at 4D Molecular Therapeutics, Inc., has been granted 50,000 stock options as part of the company's non-employee director compensation program.

Nancy Miller-Rich, a Director at 4D Molecular Therapeutics, Inc., was granted 50,000 stock options as part of the company's non-employee director compensation program.

Susannah Gray, a Director at 4D Molecular Therapeutics, received a stock option grant for 50,000 shares.

4D Molecular Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

4D Molecular Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

4D Molecular Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, auditor ratification, executive compensation, and say-on-pay frequency.

4D Molecular Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

4D Molecular Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 21, 2024, to vote on the election of a director and the ratification of the company's independent accounting firm.

RA Capital Management and its principals have filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in 4D Molecular Therapeutics, Inc.

State Street Corporation has reported beneficial ownership of 5.3% of 4D Molecular Therapeutics' common stock as of March 31, 2026.

Janus Henderson Group plc has reported a beneficial ownership of 10.3% of 4D Molecular Therapeutics, Inc. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in 4D Molecular Therapeutics Inc. following an internal realignment.

Janus Henderson Group plc has reported a beneficial ownership of 8.1% in 4D Molecular Therapeutics, Inc., holding 4,635,875 common shares.

Goldman Sachs Group and its affiliate Goldman Sachs & Co. LLC have reported a 7.5% beneficial ownership in 4D Molecular Therapeutics, Inc. common stock.